Evaxion Biotech A/S logo
Evaxion Biotech A/S EVAX
$ 5.81 -6.44%

Annual report 2024
added 12-13-2025

report update icon

Evaxion Biotech A/S Balance Sheet 2011-2025 | EVAX

Annual Balance Sheet Evaxion Biotech A/S

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-29.6 M - - - - - - - - - -

Long Term Debt

- - - 2.21 M - - - - - - - - - -

Long Term Debt Current

314 K 326 K 303 K 314 K 20 K 36 K - - - - - - - -

Total Non Current Liabilities

- - - 3.4 M - - - - - - - - - -

Total Liabilities

14.1 M 17.6 M 13.7 M 7.73 M 4.93 M 1.72 M - - - - - - - -

Retained Earnings

- - - -50.4 M - - - - - - - - - -

Total Assets

12.5 M 12.9 M 22 M 40.2 M 12 M 11.1 M - - - - - - - -

Cash and Cash Equivalents

5.95 M 5.58 M 13.2 M 32.2 M 5.83 M 9.56 M 7.43 M - - - - - - -

Book Value

-1.65 M -4.73 M 8.3 M 32.4 M 7.04 M 9.36 M - - - - - - - -

Total Shareholders Equity

- - - 32.4 M 7.04 M 9.36 M -931 K - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Evaxion Biotech A/S

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 2.14 M 2.21 M 2.29 M 974 K 1.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - 10 M 3.4 M 3.54 M 1.03 M 1.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - 14.7 M 7.73 M 7.47 M 5.83 M 7.12 M 4.93 M - - - 1.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - -55.9 M -50.4 M -42.1 M -37.5 M -31.1 M -27.3 M - - - -15.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - 41.1 M 40.2 M 24.1 M 27.7 M 34.9 M 12 M - - - 11.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - 31.4 M 32.2 M 11.9 M 18.8 M 27 M 5.83 M 7.88 M 4.08 M 6.34 M 9.56 M - - - 7.43 M - - - 468 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - 26.4 M 32.4 M 16.6 M 21.8 M 27.8 M 7.04 M - - - 9.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - 26.4 M 32.4 M 16.6 M 21.8 M 27.8 M 7.04 M 7.9 M 3.72 M 6.76 M 9.36 M - - - -931 K - - - 2.55 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Evaxion Biotech A/S, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.